Author(s):

Question: Bupropioon lisaks psühhosotsiaalsetele sekkumistele compared to ainult psühhosotsiaalsed sekkumised for loobimuse määra tõstmiseks?

Setting:

Bibliography:

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	bupropioon lisaks psühhosotsiaalsetele sekkumistele	ainult psühhosotsiaalsed sekkumised	Relative (95% CI)	Absolute (95% CI)		
Suitsetamise loobumise määr (follow-up: range 6 months to 12 months)												
47[1]	randomised trials	serious[a]	not serious	not serious	not serious	none	1846/9714 (19.0%)	900/8152 (11.0%)	**RR 1.64** (1.52 to 1.77)	**71 more per 1000** (from 57 more to 85 more)	⨁⨁⨁◯ Moderate[a]	
Suitsetamisest loobumise määr (psühhiaatriliste häiretega patsiendid)												
5[1]	randomised trials	serious[a]	not serious	not serious	not serious	none	150/1095 (13.7%)	88/1085 (8.1%)	**RR 1.67** (1.30 to 2.15)	**54 more per 1000** (from 24 more to 93 more)	⨁⨁⨁◯ Moderate[a]	
Suitsetamisest loobumise määr (psüühiliste häireteta iniemsed)												
44[1]	randomised trials	serious[a]	not serious	not serious	not serious	none	1696/8619 (19.7%)	812/7067 (11.5%)	**RR 1.63** (1.51 to 1.77)	**72 more per 1000** (from 59 more to 88 more)	⨁⨁⨁◯ Moderate[a]	
Kõrvaltoimed												
20[1]	randomised trials	serious[a]	serious[b]	not serious	not serious	none	3917/5978 (65.5%)	2827/4915 (57.5%)	**RR 1.14** (1.11 to 1.18)	**81 more per 1000** (from 63 more to 104 more)	⨁⨁◯◯ Low[a,b]	
Tõsised kõrvaltoimed												
25[1]	randomised trials	serious[c]	not serious	not serious	not serious	none	139/6094 (2.3%)	107/4531 (2.4%)	**RR 1.16** (0.90 to 1.48)	**4 more per 1000** (from 2 fewer to 11 more)	⨁⨁⨁◯ Moderate[c]	
Psühhiaatrilised kõrvaltoimed												

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	bupropioon lisaks psühhosotsiaalsetele sekkumistele	ainult psühhosotsiaalsed sekkumised	Relative (95% CI)	Absolute (95% CI)		
7[1]	randomised trials	serious[a]	not serious	not serious	not serious	none	790/2211 (35.7%)	632/2228 (28.4%)	**RR 1.25** (1.15 to 1.37)	**71 more per 1000** (from 43 more to 105 more)	⨁⨁⨁◯ Moderate[a]	
Ärevus kõrvaltoimena												
14[1]	randomised trials	serious[a]	serious[d]	not serious	not serious	none	363/3986 (9.1%)	208/3420 (6.1%)	**RR 1.42** (1.21 to 1.67)	**26 more per 1000** (from 13 more to 41 more)	⨁⨁◯◯ Low[a,d]	
Unetus kõrvaltoimena												
25[1]	randomised trials	serious[c]	not serious	not serious	not serious	none	1200/6086 (19.7%)	523/4991 (10.5%)	**RR 1.78** (1.62 to 1.96)	**82 more per 1000** (from 65 more to 101 more)	⨁⨁⨁◯ Moderate[c]	

CI: confidence interval; **RR:** risk ratio

Explanations

a. Nihke riksi tõstab pimendamise ning randomiseerimise strateegia puudulik kirjeldus uuringutes

b. Uuringutes esineb suur statistiline heterogeensus (I2 = 63%)

c. Nihke tõenäosust tõstab väike uuringute arv, puudulik pimendamine ja rühmade paigutamise ja randomiseerimise strateegia kirjeldus uuringutes.

d. Uuirngutes esineb mõõdukas statistiline heterogeensus (I2=40%)

References

1.Howes S, Hartmann-Boyce J,Livingstone-Banks J,Hong B,Lindson N. Antidepressants for smoking cessation.Cochrane Database Syst Rev; 2020.